Merck Announces Phase 3 KEYNOTE-671 Trial Met Primary Endpoint of Event-Free Survival (EFS) in Patients With Resectable Stage II, IIIA or IIIB Non-Small Cell Lung Cancer – Merck

by

  1. Merck Announces Phase 3 KEYNOTE-671 Trial Met Primary Endpoint of Event-Free Survival (EFS) in Patients With Resectable Stage II, IIIA or IIIB Non-Small Cell Lung Cancer Merck
  2. Merck ends last Keytruda trial in aggressive prostate cancer campaign, takes separate hit in lung cancer FiercePharma
  3. Merck Provides Update on Phase 3 Trials KEYNOTE-641 and KEYNOTE-789 businesswire.com
  4. Pembrolizumab Plus Standard Therapy Falls Short in mCRPC, EGFR-Mutant NSCLC Trials OncLive
  5. Merck scraps third prostate cancer study as Keytruda therapy disappoints Reuters
  6. View Full Coverage on Google News

Read original article here

Leave a Comment